TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07359820: A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Sponsor: Elevar Therapeutics · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$3,049,200

Rescue Site Savings

+$2,032,800

Unlock Full NCT07359820 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07359820 Rescue Dossier →